Statements (67)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:protein
|
| gptkbp:associated_with |
gptkb:Oncology
|
| gptkbp:can_lead_to |
poor prognosis
|
| gptkbp:code |
ERBB2 gene
|
| gptkbp:has_role |
cell differentiation
cell growth |
| https://www.w3.org/2000/01/rdf-schema#label |
HER2
|
| gptkbp:involved_in |
cell signaling
|
| gptkbp:is_associated_with |
gptkb:invasive_lobular_carcinoma
gptkb:Oncology gptkb:triple-negative_breast_cancer increased cell proliferation increased angiogenesis high-grade tumors higher risk of recurrence poor overall survival poor response to endocrine therapy |
| gptkbp:is_expressed_in |
heart tissue
brain tissue normal breast tissue |
| gptkbp:is_found_in |
cell membrane
|
| gptkbp:is_involved_in |
apoptosis
cell cycle regulation signal transduction tumorigenesis tumor heterogeneity tumor microenvironment angiogenesis cell adhesion cell migration metastasis cytokine production tumor progression drug resistance mechanisms immune evasion metabolic reprogramming tumor immune evasion epithelial-mesenchymal transition extracellular matrix interaction immune checkpoint regulation dimerization tumor microenvironment remodeling tumor immune response tumor-associated angiogenesis T-cell infiltration cancer stem cell maintenance tumor-associated macrophage recruitment |
| gptkbp:is_linked_to |
resistance to chemotherapy
resistance to hormone therapy |
| gptkbp:is_overexpressed_in |
ovarian cancer
endometrial cancer |
| gptkbp:is_part_of |
HER family of receptors
HER2 signaling pathway |
| gptkbp:is_targeted_at |
gptkb:pertuzumab
gptkb:neratinib gptkb:trastuzumab gptkb:ado-trastuzumab_emtansine gptkb:lapatinib immune checkpoint inhibitors trastuzumab biosimilars |
| gptkbp:measures |
immunohistochemistry
FISH |
| gptkbp:overexpressed_in |
20-30% of breast cancers
|
| gptkbp:bfsParent |
gptkb:pertuzumab
gptkb:trastuzumab-pkrb gptkb:Pertuzumab |
| gptkbp:bfsLayer |
6
|